Identification of JAK2 as a Mediator of FIP1L1-PDGFRA-Induced Eosinophil Growth and Function in CEL

The Fip1-like1 (FIP1L1)-platelet-derived growth factor receptor alpha fusion gene (F/P) arising in the pluripotent hematopoietic stem cell (HSC),causes 14% to 60% of patients with hypereosinophilia syndrome (HES). These patients, classified as having F/P (+) chronic eosinophilic leukemia (CEL), present with clonal eosinophilia and display a more aggressive disease phenotype than patients with F/P (–) HES patients. The mechanisms underlying predominant eosinophil lineage targeting and the cytotoxicity of eosinophils in this leukemia remain unclear. Given that the Janus tyrosine kinase (JAK)/signal transducers and activators of transcription (Stat) signaling pathway is key to cytokine receptor-mediated eosinophil development and activated Stat3 and Stat5 regulate the expression of genes involved in F/P malignant transformation, we investigated whether and how JAK proteins were involved in the pathogenesis of F/P-induced CEL. F/P activation of JAK2, Stat3 and Stat5, were confirmed in all the 11 F/P (+) CEL patients examined. In vitro inhibition of JAK2 in EOL-1, primary F/P(+) CEL cells (PC) and T674I F/P Imatinib resistant cells(IR) by either JAK2-specific short interfering RNA (siRNA) or the tryphostin derivative AG490(AG490), significantly reduced cellular proliferation and induced cellular apoptosis. The F/P can enhance the IL-5-induced JAK2 activation, and further results indicated that JAK2 inhibition blocked IL-5-induced cellular migration and activation of the EOL-1 and PC cells in vitro. F/P-stimulation of the JAK2 suppressed cells led to a significantly reduction in Stat3 activation, but relatively normal induction of Stat5 activation. Interestingly, JAK2 inhibition also reduced PI3K, Akt and NF-κB activity in a dose-dependent manner, and suppressed expression levels of c-Myc and Survivin. These results strongly suggest that JAK2 is activated by F/P and is required for F/P stimulation of cellular proliferation and infiltration, possibly through induction of c-Myc and Survivin expression via activation of multiple signaling pathways, including NF-κB, Stat3, and PI3K/Akt.

[1]  D. Frank,et al.  Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells , 2012, Leukemia.

[2]  Kun Meng,et al.  Icaritin Shows Potent Anti-Leukemia Activity on Chronic Myeloid Leukemia In Vitro and In Vivo by Regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT Signalings , 2011, PloS one.

[3]  N. Kakazu,et al.  JAK2 V617F-Dependent Upregulation of PU.1 Expression in the Peripheral Blood of Myeloproliferative Neoplasm Patients , 2011, PloS one.

[4]  G. Pottiez,et al.  Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. , 2011, Journal of proteome research.

[5]  C. Janson,et al.  PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model , 2011, Inflammation.

[6]  A. Gračanin,et al.  Jak2 Is a Negative Regulator of Ubiquitin-Dependent Endocytosis of the Growth Hormone Receptor , 2011, PloS one.

[7]  L. Chew,et al.  Concomitant FIP1L1–PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib , 2011, Leukemia & lymphoma.

[8]  Yiming Zhu,et al.  Chemoattractant-Induced Signaling via the Ras–ERK and PI3K–Akt Networks, along with Leukotriene C4 Release, Is Dependent on the Tyrosine Kinase Lyn in IL-5– and IL-3–Primed Human Blood Eosinophils , 2011, The Journal of Immunology.

[9]  Xiuqiang Wang,et al.  JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms , 2010, PloS one.

[10]  J. Cancelas,et al.  FIP1L1/PDGFRα-Associated Systemic Mastocytosis , 2010, International Archives of Allergy and Immunology.

[11]  I. Kim,et al.  Leukotactin-1/CCL15 induces cell migration and differentiation of human eosinophilic leukemia EoL-1 cells through PKCδ activation , 2010, Molecular Biology Reports.

[12]  Yan Wang,et al.  Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). , 2010, Genes & cancer.

[13]  J. Issa,et al.  JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5 , 2010, Leukemia.

[14]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[15]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[16]  I. Kim,et al.  The roles of MCP-1 and protein kinase C delta activation in human eosinophilic leukemia EoL-1 cells. , 2009, Cytokine.

[17]  Yanli Jin,et al.  Triptolide abrogates oncogene FIP1L1‐PDGFRα addiction and induces apoptosis in hypereosinophilic syndrome , 2009, Cancer science.

[18]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[19]  Yan Wang,et al.  Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients , 2009, Oncogene.

[20]  Wei-Hwa Lee,et al.  JAK pathway induction of c‐Myc critical to IL‐5 stimulation of cell proliferation and inhibition of apoptosis , 2009, Journal of cellular biochemistry.

[21]  A. Iwama,et al.  FIP1L1-PDGFRα Imposes Eosinophil Lineage Commitment on Hematopoietic Stem/Progenitor Cells* , 2009, Journal of Biological Chemistry.

[22]  R. Yeh,et al.  The molecular anatomy of the FIP1L1-PDGFRA fusion gene , 2009, Leukemia.

[23]  J. Cools,et al.  Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias , 2008, Leukemia.

[24]  G. Superti-Furga,et al.  Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. , 2008, Experimental hematology.

[25]  P. Changelian,et al.  The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. , 2008, European journal of pharmacology.

[26]  Stephen L. Abrams,et al.  Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia , 2008, Leukemia.

[27]  T. Seyama,et al.  Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha. , 2008, Biochemical and biophysical research communications.

[28]  C. Preudhomme,et al.  The severity of FIP1L1–PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus , 2007, Leukemia.

[29]  G. Altavilla,et al.  Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response? , 2007, Leukemia research.

[30]  J. Cools,et al.  Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. , 2007, Cancer research.

[31]  A. Tefferi,et al.  FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. , 2006, Leukemia research.

[32]  H. Simon,et al.  cIAP‐2 and survivin contribute to cytokine‐mediated delayed eosinophil apoptosis , 2006, European journal of immunology.

[33]  David A. Williams,et al.  The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. , 2006, Blood.

[34]  D. Hebenstreit,et al.  JAK/STAT-dependent gene regulation by cytokines. , 2005, Drug news & perspectives.

[35]  P. Marynen,et al.  The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2004, Blood.

[36]  T. Naoe,et al.  TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways , 2004, Leukemia.

[37]  D. Gilliland,et al.  Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. , 2003, Blood.

[38]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[39]  C. Wong,et al.  Tumour necrosis factor‐α‐induced expression of intercellular adhesion molecule‐1 on human eosinophilic leukaemia EoL‐1 cells is mediated by the activation of nuclear factor‐κB pathway , 2003 .

[40]  S. Rangwala,et al.  Attenuation of IL-5-mediated signal transduction, eosinophil survival, and inflammatory mediator release by a soluble human IL-5 receptor. , 1997, Journal of immunology.

[41]  M. Strath,et al.  Detection of eosinophils using an eosinophil peroxidase assay. Its use as an assay for eosinophil differentiation factors. , 1985, Journal of immunological methods.

[42]  S. Wolff,et al.  THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature , 1975, Medicine.

[43]  H. Kantarjian,et al.  The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-α-expressing cells through caspase-3-mediated cleavage of Mcl-1 , 2007, Leukemia.

[44]  A. Rossi,et al.  Cell clonality in hypereosinophilic syndrome: what pathogenetic role? , 2007, Clinical and experimental rheumatology.

[45]  C. Wong,et al.  Tumour necrosis factor-alpha-induced expression of intercellular adhesion molecule-1 on human eosinophilic leukaemia EoL-1 cells is mediated by the activation of nuclear factor-kappaB pathway. , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[46]  A. Böyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[47]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .